1. Home
  2. CFLT vs CYTK Comparison

CFLT vs CYTK Comparison

Compare CFLT & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Confluent Inc.

CFLT

Confluent Inc.

HOLD

Current Price

$30.99

Market Cap

7.7B

Sector

Technology

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$63.09

Market Cap

7.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFLT
CYTK
Founded
2014
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
7.6B
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
CFLT
CYTK
Price
$30.99
$63.09
Analyst Decision
Hold
Strong Buy
Analyst Count
28
18
Target Price
$28.73
$88.50
AVG Volume (30 Days)
7.0M
1.8M
Earning Date
04-29-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
19.63
N/A
EPS
N/A
N/A
Revenue
$1,166,748,000.00
$13,368,000.00
Revenue This Year
$18.71
$9.79
Revenue Next Year
$16.90
$302.66
P/E Ratio
N/A
N/A
Revenue Growth
21.08
N/A
52 Week Low
$15.64
$29.31
52 Week High
$31.00
$70.98

Technical Indicators

Market Signals
Indicator
CFLT
CYTK
Relative Strength Index (RSI) 71.74 50.44
Support Level $30.60 $59.25
Resistance Level N/A $65.27
Average True Range (ATR) 0.09 2.51
MACD -0.02 0.04
Stochastic Oscillator 97.53 73.68

Price Performance

Historical Comparison
CFLT
CYTK

About CFLT Confluent Inc.

Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: